Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Oct;37(5):268-72.
doi: 10.4143/crt.2005.37.5.268. Epub 2005 Oct 31.

Results of curative radiation therapy with or without chemotherapy for stage III unresectable non-small cell lung cancer

Sung-Ja Ahn  1 , Young-Chul Kim, Kyu-Sik Kim, Kyung-Ok Park, Woong-Ki Chung, Taek-Keun Nam, Byung-Sik Nah, Ju-Young Song, Mi-Sun Yoon
Affiliations

Results of curative radiation therapy with or without chemotherapy for stage III unresectable non-small cell lung cancer

Sung-Ja Ahn et al. Cancer Res Treat. 2005 Oct.

Abstract

Purpose: We retrospectively analyzed the patients who received curative radiotherapy for unresectable stage III NSCLC to investigate the impact of chemotherapy.

Materials and methods: From 1998 to 2001, the records of 224 patients who completed curative radiotherapy for NSCLC were reviewed. There were 210 males and 14 females, and their median age was 64 years (range 38 approximately 83). 54 patients had stage IIIA disease and 170 patients had stage IIIB disease. Conventional radiotherapy was given and the radiation dose ranged from 50 approximately 70 Gy with a median of 60 Gy, and chemotherapy was combined for 116 patients (52%).

Results: The median survival, the 2-year, and 5-year actuarial survival rates of all 224 patients were 15 months, 30%, and 7%, respectively. The median survival of the patients with stage IIIA and IIIB disease were 21 months and 13 months, respectively (p=0.14). The median survival of patients who received chemoradiation was 18 months compared to 14 months for the patients who received RT alone (p=0.02). Among the chemoradiation group of patients, the median survival time of the patients who received 1 to 3 cycles of chemotherapy was 16 months and that for the patients who received more than 3 cycles was 22 months (p=0.07). We evaluated the effects of the timing of chemoradiation in 57 patients who received more than 3 cycles of chemotherapy. The median survival of the patients with the concurrent sequence was 25 months and that for the patients with the sequential chemotherapy was 19 months (p=0.81).

Conclusions: For advanced stage III non-small cell lung cancer patients who completed the curative radiotherapy, the addition of chemotherapy improved the survival compared to the patients who received radiotherapy alone.

Keywords: Chemotherapy; Non-small cell lung cancer; Radiotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The overall survival of all 224 patients with stage III non-small-cell lung cancer.
Fig. 2
Fig. 2
The survival curve according to the timing of chemoradiation was shown in the patient group who received chemotherapy more than 3 cycles. (A) concurrent (N=20), (B) neoadjuvant (N=24), (C) post-radiation group (N=13).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, a concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 1998;16:3316–3322. - PubMed
    1. Dillman RO, Herndon J, Seagren SL, Eaton WL, Jr, Green MR. Improved survival in stage III NSCLC: Seven year follow-up of CALGB 8433 trial. J Natl Cancer Inst. 1996;88:1210–1215. - PubMed
    1. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: First analysis of a randomized trial of 353 patients. J Natl Cancer Inst. 1991;83:417–423. - PubMed
    1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1995;311:899–909. - PMC - PubMed
    1. Sause W, Kolesar P, Taylor S, IV, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–364. - PubMed

LinkOut - more resources